Member Info for HereforHemo

Potential things to look forward to in the days, weeks and months ahead:
•CAR-T IND
•Funding ‘opportunity’
•Broker report
•Partnership agreement for one of their product candidates
•CBR in vivo results
•Bio Defence grant
•CAR-T clinical trials
•End of year financials
•CDX update
The longer we hold the more value is created. All in my opinion.

If only everyone knew the sheer volume of good news that’s coming in the very near future then I’m sure my filter button wouldn’t be so active lol. Personally I don’t care who sells buys or holds, all I can do is give my opinion and that’s I’m very very happy to be holding this as my only share. Bring on next week..have a great weekend all, even you doubters lol

DQ that’s good to know, thanks. However, I don’t think Hemogenyx are anywhere close to fulfilling NASDAQ criteria. To me they’re just looking to asset strip at fire sale prices, if indeed that’s the plan. Think this may have taken primary focus but hopefully Vlad has had time to submit the IND today, should find out if he had in the morning. Not sure what RNS will hit first now but whichever it is it’s going to be good news.

This is like waiting for a London bus. You wait for ages then 3 arrive at the same time. Think I can just see one in the distance..just passing the dentist.

JHFH you have exactly the same take on the situation as me, which is hardly surprising as some people believe we are the same person lol. The bottom line is this, you either believe IND is being submitted soon, maybe as early as today, you believe there’s an opportunity Hemogenyx are progressing, you believe CBR in vivo results are due or you don’t. You either buy, sell, hold or short accordingly. Whatever you do should have nothing t do with this board and everything to do with your own research. People already know my views so I won’t repeat them.

Negative, the wait is a little longer. Positive, I expected it to be at placing price before it came out. Hopefully tomorrow both will come true.

Just realised I’d only filtered 4/5th of the w**kers who pop up and post on here, rectified now though. As for getting in before this takes off with IND being submitted, I’m not so sure. Still I’m over optimistic with timescales so what do I know. Still I’m in Banff at the moment so perhaps I’ll find someone on the ski slopes tomorrow who’s invested in HEMO and he’ll tell me what is going on?

Considering I’ve always thought we’d get news this week, and Friday is not the best day to release it, by way of deduction I’d say it’s probably worth getting up early tomorrow…around RNS o’clock. GLA

Wouldn’t be surprised to see us back to placing price at the close today. Just a hunch.

Hulver I hope the dream becomes a reality for you, a very noble aspiration. Good luck!

Someone doing due diligence? I’ll take you back to my post on the 6th.

There’s no doubt in my mind that Hemogenyx are now in a truly fantastic position. They’ve completed a drug development model for J&J, they’ve jointly developed a bi-specific antibody with Eli Lilly, they’re developed HEMO CAR-T in collaboration with Penn University and to top it all they’ve developed a totally unique CBR platform to potentially treat all known viruses, with at least a year’s financial runway and all candidates fully patent protected. All being well investors can expect a major partner announcement, an IND application for CAR-T and CBR results announced in the very near future and personally I’m expecting clinical trials to commence next month. Becoming a clinical company should see a major rerate on the SP but ironically it’s not the most exciting thing in the HEMO toolbox. That’s because IF CBR works, and I understand Vlad is VERY confident it will, then we have a total paradigm shift in science. To me, if in vivo results are positive there’s only one outcome, Hemogenyx will be bought by a major and for a very large sum. So yes, people can highlight the risk involved with biotech but for this company, at this price the rewards could be staggering. I may of course be completely wrong but for me it’s a short, medium and long term buy and hold.

Not long now for things to develop. GLA

Pumpky the fact you don’t know all the FDA work is now done online shows just what a ****ing idiot you are. Had enough of your stupid whining..filtered.

Pingu I’m still confident of IND this week and I’ll stick to my prediction of Hemogenyx becoming a clinical company next Month. Nobody knows where the SP will go but with other major news to be issued in parallel it certainly isn’t going any lower.

However you look at it we’re in an era of ongoing pandemic threats. To date there’s only one unique solution that could cure them all, and that’s CBR. In vivo results are due shortly and if successful i fully expect it to be fast tracked into clinical trials.

https://www.science.org/content/article/incredibly-concerning-bird-flu-outbreak-spanish-mink-farm-triggers-pandemic-fears

Personally I don’t give a toss who the 500k seller is, or whether there’s more than one of them. At the price they’re selling at all I know is that to date they’ve probably cost themselves a minimum of around £150-200k by selling now, rather than waiting a very short amount of time. That to me is the definition of an imbecile but each to their own, sometimes all you can do is chuckle lol. Investing certainly isn’t for everyone.

HT Hemogenyx were always aiming for week commencing the 6th for IND and I’m confident they are on schedule to achieve it.

HT his friends call him David lol.

https://hemogenyx.com/people/h-michael-shepard-phd/

Sir Marc, Vlad and David. Don’t think there’s any better individuals in a Biotech small cap.

https://hemogenyx.com/investors/announcements/announcement/2019/Hemogenyx-Pharma-Plc---Hemogenyx-scientific-advisor-receives-Lasker-Award/

When investing I always look at the people as well as the science. To have a Chairman who’s advised over 20 of the leading Pharmaceutical and Biotech companies in the world, it’s always a plus. Quite happy to be patient, it’s always been a question of ‘when’ not ‘if’ for me holding Hemogenyx.

https://hemogenyx.com/people/sir-marc-feldmann-ac-faa-frs-frcp-frcpath-fmedsci/

There’s no doubt in my mind that Hemogenyx are now in a truly fantastic position. They’ve completed a drug development model for J&J, they’ve jointly developed a bi-specific antibody with Eli Lilly, they’re developed HEMO CAR-T in collaboration with Penn University and to top it all they’ve developed a totally unique CBR platform to potentially treat all known viruses, with at least a year’s financial runway and all candidates fully patent protected. All being well investors can expect a major partner announcement, an IND application for CAR-T and CBR results announced in the very near future and personally I’m expecting clinical trials to commence next month. Becoming a clinical company should see a major rerate on the SP but ironically it’s not the most exciting thing in the HEMO toolbox. That’s because IF CBR works, and I understand Vlad is VERY confident it will, then we have a total paradigm shift in science. To me, if in vivo results are positive there’s only one outcome, Hemogenyx will be bought by a major and for a very large sum. So yes, people can highlight the risk involved with biotech but for this company, at this price the rewards could be staggering. I may of course be completely wrong but for me it’s a short, medium and long term buy and hold.